IL-6 Antibody (YA7499)
(Synonyms: IFNB2, IL6, Interleukin-6, IL-6, B-cell stimulatory factor 2, CTL differentiation factor, Hybridoma growth factor, Interferon beta-2, BSF-2, CDF, IFN-beta-2)Based on 1 Customer Validation
IL-6 Antibody (YA7499) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to IL-6.
-
Host:
Rabbit
-
Isotype:
IgG
-
Application:
WB, ICC/IF, IP, ELISA
-
Reactivity :
Mouse
-
Formulation:
Supplied in PBS (pH7.4) containing 50% glycerol, 0.05% Proclin 300, 0.05%BSA
-
Conjugation:
Non-conjugated
Applications
| Application |
WB
WB: Western Blot
|
ICC/IF
ICC/IF: Immunocytochemistry/
Immunofluorescence |
ELISA
ELISA: Enzyme Linked Immunosorbent Assay
|
IP
IP: Immunoprecipitation
|
|---|---|---|---|---|
| Dilution Ratio | 1:2000-1:10000 | 1:200-1:1000 | 1:5000-1:20000 | 1:50-1:200 |
Product Details
IL-6 Antibody (YA7499) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to IL-6.
-
Host Rabbit
-
Clonality Monoclonal,Recombinant
-
Species ReactivityMouse
-
Observed Molecular WeightObserved band size: 21 kDaNote: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 24 kDa
The exact sequence is proprietary to MCE.
Endogenous
Protein A affinity purified
Non-conjugated
Unmodified
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in PBS (pH7.4) containing 50% glycerol, 0.05% Proclin 300, 0.05%BSA
-
Concentration
Batch-dependent, Please check the COA for the concentration of each lot. Check Lot Concentration
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Verification Images
-
Western blot analysis was performed by loading 0.1 μg (Lane 2), 0.2 μg (Lane 3) and 0.5 μg (Lane 4) of IL-6 using IL-6 antibody. Proteins were transferred onto a 0.45 μm PVDF membrane using the Trans-Blot® Turbo™ system for 13 min. The membrane was then blocked with 5% nonfat milk in TBST (HY-K1025) for 1 h at room temperature. The primary antibody (1:1000) and loading control antibody GAPDH Antibody (HRP) (HY-P80954A) (1:5000) were diluted in 5% nonfat milk in TBST and incubated with the membrane overnight at 4°C. After washing, the membrane of primary antibody was incubated with HRP-conjugated goat anti-rabbit/mouse IgG secondary antibody (HY-P8001/HY-P8004) (1:5000) diluted in 5% nonfat milk in TBST for 1 h at room temperature. Protein bands were visualized using an Ultra High Sensitivity ECL detection kit (HY-K1005).
Background
-
Function
IL-6 is a pleiotropic cytokine that regulates immune response, acute inflammation, tissue regeneration, metabolism, and stromal activation[1][2]. Mechanistically, IL-6 binds IL-6Rα and recruits gp130, activating JAK/STAT3 signaling and downstream transcriptional programs[1][3]. Disease relevance depends strongly on receptor context: membrane IL-6Rα supports classic signaling, whereas soluble IL-6Rα enables trans-signaling in gp130-expressing cells and drives pro-inflammatory activity[1][4]. Compared with these receptor forms, gp130 is broadly expressed, while IL-6R expression is restricted to selected cells such as hepatocytes and leukocytes, explaining cell-type-selective responsiveness[1]. In vascular endothelial cells, IL-6 trans-signaling induces MCP-1 through coordinated JAK/STAT3 and PI3K/AKT activation[5]. In proliferative vitreoretinopathy models, IL-6 promotes retinal pigment epithelial proliferation and epithelial-mesenchymal transition through JAK1/STAT3 signaling[6]. For experimental intervention, tocilizumab, a humanized anti-IL-6R antibody, blocks IL-6 signaling and improves rheumatoid arthritis outcomes in controlled clinical studies[7][8].
-
Subcellular Localization
Secreted
-
Expression
Tissue_Specificity: Produced by skeletal muscle
Induction: Plasma levels are highly increased upon exercise, due to enhanced production by contracting skeletal muscles. Up-regulated by coagulation factor Xa (F10) in PAR-1 (F2R)-dependent manner in cardiac fibroblasts (PubMed:34831181) -
Isoforms & Post-Translational Modification
P05231: 212 amino acids, molecular weight 23718 Da.
-
Subunit
Component of a hexamer of two molecules each of IL6, IL6R and IL6ST; first binds to IL6R to associate with the signaling subunit IL6ST (PubMed:12829785)
-
SwissProt ID
-
Synonyms
IFNB2, IL6, Interleukin-6, IL-6, B-cell stimulatory factor 2, CTL differentiation factor, Hybridoma growth factor, Interferon beta-2, BSF-2, CDF, IFN-beta-2
Documentation
-
Data Sheet (261 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
User Guide for Antibodies (1077 KB)
References
[1]. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci. 2012;8(9):1237-47. doi: 10.7150/ijbs.4989. Epub 2012 Oct 24. PMID: 23136552; PMCID: PMC3491447. et al. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci. 2012;8(9):1237-47. [Content Brief]
[2]. Danese S, et al. Interleukin-6: a therapeutic Jekyll and Hyde in gastrointestinal and hepatic diseases. Gut. 2010 Feb;59(2):149-51. [Content Brief]
[3]. Reeh H, et al. Response to IL-6 trans- and IL-6 classic signalling is determined by the ratio of the IL-6 receptor α to gp130 expression: fusing experimental insights and dynamic modelling. Cell Commun Signal. 2019 May 17;17(1):46. [Content Brief]
[4]. Maes M, et al. Targeting classical IL-6 signalling or IL-6 trans-signalling in depression? Expert Opin Ther Targets. 2014 May;18(5):495-512. [Content Brief]
[5]. Zegeye MM, et al. Activation of the JAK/STAT3 and PI3K/AKT pathways are crucial for IL-6 trans-signaling-mediated pro-inflammatory response in human vascular endothelial cells. Cell Commun Signal. 2018 Sep 5;16(1):55. [Content Brief]
[6]. Chen X, et al. Interleukin-6 promotes proliferative vitreoretinopathy by inducing epithelial-mesenchymal transition via the JAK1/STAT3 signaling pathway. Mol Vis. 2020 Jul 29;26:517-529. [Content Brief]
[7]. Ohsugi Y, et al. The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2008 May;8(5):669-81. [Content Brief]
[8]. Emery P, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008 Nov;67(11):1516-23. [Content Brief]